Fox Chase Cancer Center

This phase 2 trial is testing a combination of two drugs—nivolumab and ramucirumab—in 36 people with advanced non-small cell lung cancer that has returned or spread. Participants have already had immunotherapy. The goal is to see if the combo can control the disease by boosting t…

This early-phase trial tests a new type of radiation called pulsed low-dose-rate (PLDR) for people with pancreatic cancer that cannot be removed right away. The radiation is given in small, spaced-out bursts along with the chemotherapy drug gemcitabine. The goal is to see if this…

This study tests a combination of two drugs, nivolumab and axitinib, in people with advanced kidney cancer. The goal is to find the safest dose and see how well the drugs shrink tumors. About 98 participants will take part, including those who have had prior treatment and those w…

This study tests whether a combination of three drugs (paricalcitol, hydroxychloroquine, and losartan) can safely modify the supportive tissue around pancreatic tumors before surgery. About 20 adults with resectable pancreatic cancer will take these drugs for at least 4 weeks bet…

This study tests a treatment plan to avoid major surgery for early-stage rectal cancer. Patients first receive chemotherapy, then a small surgery to remove the tumor, followed by radiation and more chemo. The goal is to see if this approach can cure the cancer while keeping the r…

This phase 2 trial tests two oral drugs, ribociclib and everolimus, in people with advanced dedifferentiated liposarcoma or leiomyosarcoma who have had at least one prior treatment. The goal is to see if the combination can stop or slow tumor growth. About 48 participants will ta…

This early-phase study tests a new way to treat advanced solid tumors by combining low-dose radiation with a drug called 5-aminolevulinic acid (ALA). The drug is thought to make cancer cells more sensitive to radiation, allowing lower doses to be used and potentially reducing har…

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to a standard three-drug chemotherapy regimen (carboplatin, pemetrexed, and bevacizumab) helps people with advanced non-squamous lung cancer live longer without their disease worsening. The study enrolls …

This phase 2 trial is testing whether adding the immunotherapy drug atezolizumab to a standard combination of chemotherapy (paclitaxel) and two targeted drugs (trastuzumab and pertuzumab) is safe and effective for people with advanced HER2-positive breast cancer that has spread. …

This pilot study is testing whether a less frequent dosing schedule of the drug enfortumab vedotin (EV), given alone or with pembrolizumab, can still control advanced bladder cancer. About 60 adults with locally advanced or metastatic urothelial carcinoma will receive EV on a mod…

This study looks at whether switching between two chemotherapy drugs (FOLFOX and FOLFIRI) can reduce side effects in people aged 65 and older with metastatic pancreatic cancer. The goal is to find a treatment that is easier to tolerate than the standard three-drug regimen. 37 par…

This study looks at whether a protein called TOPO2A can help predict if the chemotherapy drugs doxorubicin or Doxil will shrink tumors in people with soft tissue sarcoma. About 24 patients whose next treatment plan includes one of these drugs will provide tumor tissue for testing…

This study examines stored tumor samples from 15 people with kidney or bladder cancer who initially responded to immune checkpoint therapy but later developed new tumors. Researchers will compare the genetic and tissue features of the original and new tumors to understand how the…